Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 18;7(1):7.
doi: 10.1186/s41927-023-00326-x.

Drug-related problems reported by patients with rheumatic diseases: an observational study

Affiliations

Drug-related problems reported by patients with rheumatic diseases: an observational study

Lex L Haegens et al. BMC Rheumatol. .

Abstract

Background: Drug-related problems can negatively influence treatment outcome and well-being for patients with rheumatic diseases. Thus, it is important to support patients in preventing or resolving drug-related problems as quickly as possible. To effectively develop interventions for this purpose, knowledge on the frequency and character of drug-related problems is needed. Therefore, this study aims to quantify and characterize drug-related problems reported by patients with inflammatory rheumatic diseases along their treatment process.

Methods: A prospective observational study was conducted in a Dutch outpatient pharmacy. Adult patients with rheumatic diseases that were prescribed medication by a rheumatologist were questioned about experienced DRPs by telephone 4 times in 8 weeks using a structured interview-guide. Patient-reported DRPs were scored on uniqueness (i.e., if a specific DRP was reported in multiple interviews by one individual, this was counted as one unique DRP) and were categorized using a classification for patient-reported DRPs and analysed descriptively.

Results: In total, 52 participants (median age 68 years (interquartile range (IQR) 62-74), 52% male) completed 192 interviews with 45 (87%) participants completing all 4 interviews. The majority of patients (65%) were diagnosed with rheumatoid arthritis. Patients reported a median number of 3 (IQR 2-5) unique DRPs during interview 1. In subsequent interviews, patients reported median numbers of 1 (IQR 0-2), 1 (IQR 0-2) and 0 (IQR 0-1) unique DRPs for interviews 2-4 respectively. Participants reported a median number of 5 (IQR 3-9) unique DRPs over all completed interviews. Unique patient-reported DRPs were most frequently categorized into (suspected) side effects (28%), medication management (e.g., medication administering or adherence) (26%), medication concerns (e.g., concerns regarding long-term side-effects or effectiveness) (19%) and medication effectiveness (17%).

Conclusions: Patients with rheumatic diseases report various unique DRPs with intervals as short as two weeks. These patients might therefore benefit from more continuous support in-between contact moments with their healthcare provider.

Keywords: Drug-related problems; Observational; Patient-reported; Rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Unique drug-related problems per patient per interview. DRP, drug-related problem; Legend: , outlier (value outside 1.5 times the interquartile range above the upper quartile or below the lower quartile)
Fig. 2
Fig. 2
Total number of unique drug-related problems per type per interview. *Category ‘Other’ consists of types that accounted for less than 5% of the total number of unique DRPs: ‘Information needs’, ‘Contra-indications’ and ‘Logistics’

Similar articles

Cited by

References

    1. Abbasi M, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234:10018–10031. doi: 10.1002/jcp.27860. - DOI - PubMed
    1. Burkhart PV, Sabaté E, Adherence to long-term therapies: evidence for action. (2003) - PubMed
    1. Van Den Bemt BJF, et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36:2164–2170. doi: 10.3899/jrheum.081204. - DOI - PubMed
    1. Vlieland ND, Gardarsdottir H, Bouvy ML, Egberts TCG, van den Bemt BJF. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatol (United Kingdom) 2016;55:704–709. - PubMed
    1. Nauman J, et al. Global incidence and mortality trends due to adverse effects of medical treatment, 1990–2017: a systematic analysis from the global burden of diseases, injuries and risk factors study. Cureus. 2020 doi: 10.7759/cureus.7265. - DOI - PMC - PubMed

LinkOut - more resources